Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
Latest Information Update: 08 Nov 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms HAMMER I
Most Recent Events
- 05 Nov 2024 Status changed from active, no longer recruiting to completed.
- 29 May 2024 Status changed from recruiting to active, no longer recruiting.
- 11 Dec 2023 Planned End Date changed from 1 Mar 2025 to 1 Jun 2025.